Genetic diversity of hemagglutinin gene of A(H1N1)pdm09 influenza strains isolated in Taiwan and its potential impact on HA-neutralizing epitope interaction. by Łepek, Krzysztof et al.
Genetic diversity of hemagglutinin gene of A(H1N1)pdm09 influenza strains isolated in 
Taiwan and its potential impact on HA-neutralizing epitope interaction 
Running title: HA mutation in Ab-binding interface
Krzysztof Łepek 1*, Beata Pająk 2,3 * , Paweł Siedlecki4, Marcin Niemcewicz5, Janusz Kocik5, 
Ho-Sheng Wu6, Ji-Rong Yang6, Krzysztof Kucharczyk1, and Bogusław Szewczyk3
* K. Lepek and B. Pajak contributed equally to an article
1University of Gdansk and Medical University of Gdansk, Gdansk, Poland;  2 BioVectis Ltd, 
Warsaw, Poland; 3Mossakowski Medical Research Centre, Warsaw, Poland; 4Institute of 
Biochemistry and Biophysics, Warsaw, Poland; 5Military Institute of Hygiene and 
Epidemiology, Pulawy, Warsaw, Poland; 6Taiwan Centers for Disease Control, Taipei, Taiwan 
Key words: A(H1N1) influenza, HA, neutralizing Ab, MSSCP, Taiwan isolates
 Correspondence to:
Beata Pajak, PhD, BioVectis Ltd,
Pawińskiego 5a/blok d, 02-106 Warsaw, Poland
Tel/fax: (+48) 22 6687147/ 22 6687164
e-mail: beata.pajak@biovectis.com
1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
1
Abbreviations and acronyms
Ab – antibody
CDC – Centers for Disease Control
HA – hemagglutinin
MSSCP – Multitemperature Single Strand Conformation Polymorphism
PCR – Polymerase Chain Reaction
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Abstract
Pandemic influenza A(H1N1)pdm09 virus is a global health threat and between 2009-
2011 it became the predominant influenza virus subtype circulating in the world. We describe 
the MSSCP (Multitemperature Single Strand Conformation Polymorphism) analysis of the 
hemagglutinin (HA) region encompassing major neutralizing epitope in pandemic influenza 
isolates from Taiwan. In isolates obtained in 2010 and 2011, several genetically distinct 
changes have appeared. The majority of changes in HA protein, have not resulted in 
significant modifications, however three modifications were localized in epitope E of H1 and 
one was  part of interface binding antibodies BH151 and HC45, which might make the current
vaccine less effective. Taking into account the possibility of the emergence of influenza A 
with antibody evading potential, the MSSCP method provides an alternative approach for 
detection of minor variants which escape detection by conventional Sanger sequencing.
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Introduction
Influenza A is a serious disease causing recurring outbreaks with significant negative 
effects on the general health status globally as well as on the economy of affected populations.
In April of 2009 a novel strain of (H1N1) swine-origin influenza A was reported in Mexico 
and the United States.1-3 The rapid spread of this virus to over 70 countries of the world urged 
the WHO to raise its pandemic alert level to the highest phase 6 by June 11, 2009. This new 
A(H1N1)pdm09 virus was found to be a triple reassortant containing a combination of gene 
segments of swine, human and avian origin.4-6 The 2009 pandemic influenza A turned out to 
be relatively mild in its symptoms when compared to other strains responsible for previous 
pandemics. Most individuals infected with the 2009 pandemic H1N1 strain usually developed
uncomplicated illness with full recovery within a week. However, this may be a transient 
situation because influenza viruses are constantly undergoing changes, both by antigenic drift 
(mutations due to the error-prone genomic RNA amplification) as well as by antigenic shift 
(exchange of genomic segments during co-infection by two different strains). The best 
example of these phenomena was the 1918 Spanish flu pandemic virus. The initial outbreak 
was relatively mild in terms of clinical impact, but had acquired higher virulence when it 
returned in the next season. Changes are in some cases gradual and more predictable. Despite 
this fact the rate of genome mutation is high enough to cause the replacement of circulating 
strains every 3-5 years with variants that underwent antigenic changes sufficient for 
substantial or complete evasion of existing antibody response. Therefore, it is crucial to 
monitor, not only the mutations leading to resistance against antiviral drugs, but also those 
that modify the most important viral epitopes. The latter lead to gradual weakening of the 
antigen-antibody interactions and therefore reduce the efficacy of existing vaccine.
The viral surface protein hemagglutinin (HA) is the primary target for neutralizing 
antibodies in natural infections.7 The antigenic variation of HA is the main mechanism 
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employed by the influenza virus to escape the response of the host immunological system. 
The HA of the pandemic A(H1N1)pdm09 strain has changed relatively little in  its genetic and
antigenic characteristics since it emerged in 2009. In 2010 a genetically distinct variant 
containing several amino acid changes in hemagglutinin and neuraminidase has emerged in 
Singapore, Australia and New Zealand. It was a dominant strain in the second and third 
quarters of 2010 in these countries, although it did not represent a significant antigenic change
of the virus.8
In this study we present an analysis of the HA region encompassing the main 
neutralizing epitope of HA from Taiwan isolates of flu seasons 2009-2011. Isolates of 2010 
and 2011 from these samples show significant changes in HA amino acid composition. Three 
of the detected mutations are likely to affect the virus-antibody interaction. 
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Results
 Nineteen clinical specimens (throat or nasal swabs) from outpatients with influenza-
like illnesses, who developed severe complications, were collected in Taiwan during the 2009-
2011 flu season (Table 1). To determine viral genotype, partial nucleotide sequences 
(positions 393-1182) of the HA gene were first analyzed by RT-PCR using primers published 
by WHO. All the isolates in this study were characterized as A/California/07/2009-like 
viruses. To verify whether the observed clinical diversity could be correlated with genetic 
alterations or the presence of minor genetic variants, the isolates were further analyzed. 
Bearing in mind the crucial role of hemagglutinin mutations for influenza virus virulence, 
representative HA gene fragments encompassing nucleotides 125 to 302 were amplified from 
cDNAs as described in Materials and Methods. This region corresponds to a fragment of 
influenza virus HA1 polypeptide starting 25 amino acids (H1 numbering is used throughout 
this paper) after the N-terminal signal peptide of hemagglutinin. A crucial part of the influenza
A/H1N1 epitope reacting with neutralizing antibodies is located within this region. To check 
for the presence of minor genetic variants of the A(H1N1)pdm09 pandemic strains within the 
obtained amplicones, we performed MSSCP (Multitemperature Single Strand Conformation 
Polymorphism) analysis. 
MSSCP is a native electrophoretic separation performed under sequentially changed 
gel temperature. This improves the sensitivity of mutation detection and reduces time of 
analysis. The temperature changes increase the probability for the PCR products to adopt 
different ssDNA conformations during the electrophoretic run if they contain nucleotide 
substitutions All the amplified HA fragments, including corresponding fragments of the 
reference seasonal (s) (A/Brisbane/59/2007) and pandemic (p) (A/Mexico/4486/09) strains, 
were denatured and the resulting ssDNA fragments were subjected to the native 
electrophoresis in optimal conditions for the MSSCP analysis (15-10-5 °C, 450 Vxh/per 
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phase, 10% PA). Results of this experiment (after visualization with silver stain) are shown in 
Fig. 1. According to the electrophoretic profiles (Fig. 1), none of the samples contains 
fragments corresponding to the predominant influenza A seasonal strain (s) which excludes 
the possibility of co-infection with seasonal and pandemic strains. Samples designated as 
2009-02626, 2009-00940, 2009-08542, 2010-00842, 2010-06031, 2011-02054, 2011-00623, 
2009-06078, 2009-04909, 2009-00937, 2009-08575, 2011-04512, 2011-02068 and 2011-
04611 exhibited MSSCP profiles identical to the reference pandemic strain, while the 
electrophoretic profiles of five samples: 2010-03994, 2011-01219, 2010-01164, 2010-05270 
and 2010-05347 were different from that of the pandemic reference strain. For further 
analysis, if profiles reflected distinct DNA sequences, ssDNA bands from the samples 
indicated by arrows in Fig. 1 were extracted from the gel, re-amplified as described in 
Materials and Methods, and the PCR products were Sanger sequenced. Additionally, the 
reference pandemic ssDNA bands were analyzed in the same manner.
Sanger sequencing of the ssDNA bands confirmed that fourteen out of the nineteen 
analyzed samples, were identical with the A(H1N1)pdm09 pandemic strain reference 
sequence (Table 2). For the five samples with electrophoretic profiles different from the 
reference strain, Sanger sequencing revealed the presence of many point mutations. Schematic
representation of all detected mutations and their localization within analyzed HA amplicone 
are presented in Fig. 2. Sample 2010-03994 contained two point mutations, 2011-01219 – 
eight, 2010-01164 – three, 2010-05270 – seven and 2010-05347 – five. Six mutations were 
present in more than one sample (Fig. 2), and nine were unique to single isolates. It seems 
unlikely that mutations arose during the short passages of the original virus from swabs in 
MDCK cells.
DNA codons containing detected point mutations were translated to amino acids and 
compared with the pandemic reference sequence. Furthermore, their physico-chemical 
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properties and localization within HA protein structure were also determined. All detected 
point mutations as well as corresponding changes of amino acids, in comparison to reference 
sequence, are summarized in Table 2. Two mutations (TAC>AAC, GTA>ATA) close to the 
vicinity of 3' end of the amplicones, were not analyzed as they were localized within the 
primer binding region. Five mutations were synonymous substitutions (Table 2), that did not 
affect the HA protein sequence. In three cases the mutations led to substitutions preserving the
physico-chemical properties of the encoded amino acids. However, some of the non-
synonymous substitutions affected the physico-chemical properties of amino acids (Table 2). 
Three point mutations (GTA>GGA, GCC>GAC, GAG>AAG), leading to amino acid changes
(valine (V)›glycine (G), alanine (A)›aspartic acid (D), glutamic acid (E)›lysine (K) 
respectively), were localized in a region presumed to be  part of epitope E of H1. To check if 
these changes could affect HA-Ab binding and modulate the potential immune response 
against A(H1N1)v, we analyzed this region by molecular modeling and estimated the possible
impact on vaccine effectiveness.
Using sequence based structural alignment method we have matched the HA1 
structure of H1 hemagglutinin (3ZTN) with the neutralizing antibody directed to H3 
hemagglutinin from 1QFU, the 3-D structures were processed and aligned to obtain maximum
resemblance of their HA-Ab binding interfaces. According to Figure 3, one of the detected 
mutations - E66K was localized in an HA-Ab binding interface.
Substitutions in the amino acid sequence, that distinguish a circulating strain from a 
vaccine strain, can be characterized by antigenic distance measured by values like P-value or 
pepitope 9 and then used for determination of how these substitutions may influence the vaccine 
effectiveness level predicted by a previously established mathematical model. We provide 
such quantification based on five substitutions. All calculations are described in detail in 
Materials and Methods. The calculated pepitope value based on substituted amino acids located 
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in epitope E, shows that these substitutions can result in 17.5% decrease of the predicted 
vaccine efficacy.
The mutated fragments listed in Table 2 were compared with available HA sequences 
of Taiwan pandemic influenza isolates deposited in the NCBI and EpiFlu data banks. The 
phylogenetic tree constructed for the 935 nt HA gene fragment, showed that the isolates may 
be divided into several clusters (Fig. 4). The isolates described in this work form a 
distinguishable cluster except isolate 2010-01164 which shares the V47G mutation with a 
group represented by isolate EPI382342. It should be pointed out that the A48D and E66K 
mutations identified here were not found in any other group of isolates that were subjected to 
comparative analysis. They may therefore represent novel changes in HA which appeared in 
the 2010/2011 flu season and suggest a short-term or geographically limited emergence of 
influenza A virus strains with a high antibody evading potential
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Discussion
Over four years have passed since the emergence of a novel H1N1 influenza A virus 
(A(H1N1)v) which caused the first global pandemic in the 21st century. The virus is still 
circulating in many countries, though at a much lower level than in its peak season of 2009-
2010.10 The impact of A(H1N1)v during the upcoming seasons will be directly correlated with
the immunity of the population provided the virus does not undergo significant antigenic 
changes.11 So, as long as the virus is genetically stable and the percentage of population 
resistant to infection is high (immunity being attained either by vaccinations or prior 
exposures to cross-reacting strains), it should not pose a major risk to public health. However, 
the influenza virus is a master of immune evasion and the possibility of an explosive 
emergence of new mutants of A(H1N1)v cannot be excluded.
The evasion of the host immune response by an influenza virus can be accomplished 
by at least three ways. Firstly, by sequential changes in HA (and other influenza virus genes) 
owing to the error-prone copying of the RNA genome by the viral RNA polymerase; this 
phenomenon is called as antigenic drift. Second, by much more abrupt changes due to 
antigenic shift during co-infection with different HA subtypes; it can be described as 
importation by reassortment of a gene encoding a different HA subtype concurrently with or 
without other viral gene segments. The third mode is a special case of the antigenic shift 
involving intrasubtypic reassortment which may occur during co-infection with two different 
strains of the same serotype. The HA serotype in the progeny virus which underwent 
reaasortment remains the same, though the HA sequence may differ significantly from the HA
sequences of the parental viruses.
The intrasubtypic reassorment may be particularly dangerous when two major strains 
of the same serotype co-circulate in an area, as was the case with the seasonal and pandemic 
A(H1N1) viruses. We showed previously that among patients in Polish hospitals co-infection 
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with these two strains was observed at a fairly high frequency.12 In contrast, in the selected 
samples diagnosed as pandemic A(H1N1)pdm09 in Taiwan, mixed infections with seasonal 
and pandemic strains were not detected, but instead some samples exhibited unique, specific 
electrophoretic profiles, different from the A/Mexico/4486/09 reference pandemic strain. Five
out of nineteen samples contained point mutations. Notably, all samples isolated in 2009 were
identical to the reference sequence, even though originating from Mexico and the mutations 
were observed only in samples isolated in 2010 and 2011, suggesting geographically limited 
virus evolution. 
 To assess the potential impact of the detected genetic changes on the virus fitness, we 
analyzed them more closely. We based our conclusions on the epitope mapping done by Deem
and Pan13 in which epitopes A-E of H3 hemagglutinin were aligned with the corresponding 
amino acids in H1 hemagglutinin. After sequence alignment, similarity of the epitopes was 
verified by 3-D structure alignment of H1 and H3 hemagglutinins. Therefore we refer to this 
bioinformatically mapped regions of H1 as epitopes A-E of H1 hemagglutinin. Three amino 
acid substitutions affecting their physico-chemical properties: (GTA>GGA, GCC>GAC and 
GAG>AAG), detected in three Taiwanese isolates localized to the HA region presumed to be 
a part of the epitope E of H1.13 It is also worthy to point out that residue 66 (E) of H1 
hemagglutinin is also a part of nine amino acid sequence (ILGNPECEL) listed among 
predicted epitopes for A2 supertype of MHC Class I molecule14 by Influenza Research 
Database15 
Hemagglutinin is a homo-trimer with each of the subunits comprising two 
polypeptides: HA1 and HA2. They fold into an α-helical stem and a globular domain, both of 
which can interact with the host cell membrane. Also neutralizing antibodies can bind to the 
both structures, as seen in crystallographic studies e.g, 3ZTN or 1EO8, but primarily they 
target the globular domain, where the HA receptor binding site is also located.16,17 Based on 
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the approach proposed by Deem and Pan13 we used data for H3 hemagglutinin from the 1QFU
complex and matched its structure with that of H1 hemagglutinin (3ZTN) to predict their 
interaction interface. The HA-Ab interface with the BH151 antibody is formed by 14 residues 
(50-54, 65-70 and 81-85 of HA1). The E66K mutation (Fig. 3) is within this interface and 
could affect it as it changes both the charge and size of the amino acid. Single mutations 
within HA-AB interface, or even those located in its close vicinity, have already been shown 
to allow viruses to escape neutralization.18 Mutations of the interface residue D54 to N or to Y
make the influenza virus immune to the HC45 and BH151 antibodies.19,20 This effect may be 
caused by introducing a new glycosylation site.21  It is noteworthy that the mutation E66K 
may create a new glycosylation site and residue 66 is in close contact with D54, forming a 
hydrogen bond with its main chain in the crystal structure 1EO8. 
On the other hand, although mutations at a protein-protein interface may be a strong 
indication of structural hindrances hampering complex formation, there are also studies 
showing the ability of antibodies to bind protein variants with one or a few amino acids 
changed.20, 22 The close proximity to a known escape mutation residue, exposure and interface 
location suggest the major role of residue 66 in modulating HA-Ab affinity. Nevertheless, this
hypothesis needs further studies. 
It is also worth mentioning that the observed substitutions present in epitope E of H1 
may affect vaccine effectiveness when they become widespread. The vaccine effectiveness 
undergoes annual changes, partially due to antigenic distances between the recommended 
vaccine strain and the circulating strain.13 One of factors to quantify such antigenic distance is 
peptope value which describes the highest fraction of substituted amino acids in all epitopes.23, 24 
Recent studies showed that vaccine effectiveness correlates with the pepitope value, thus one can
quantify the impact of substituted amino acids on the predicted level of vaccine effectiveness 
for influenza-like illnesses, which is 52.7%.24 According to our pepitope and vaccine 
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effectiveness calculations , the five substitutions found in epitope E of HA can decrease the 
predicted vaccine effectiveness from 52.7% to 35.2%. Obviously, there are many other factors
that can alter the vaccine effectiveness. Although the presented calculations are only based on 
available epidemiological data, conclusions derived from such mathematical models may be 
useful in future understanding of influenza virus diversity.24
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Materials and Methods
Sample collection and virus propagation
Clinical specimens (throat or nasal swabs) from outpatients (southern, eastern, 
northern and central Taiwan communities) with influenza-like illnesses and from hospitalized 
patients who developed severe complications, were collected and transported to the 
laboratories of the influenza surveillance network in Taiwan, which is coordinated by the 
Centers for Disease Control (Taiwan CDC), for influenza diagnosis using virus culture or/and 
real-time RT-PCR. All influenza isolates from positive cases were transported to the Taiwan 
CDC where they were shortly passaged in MDCK cells at 34°C in serum free DMEM 
medium (Life Technologies, cat no. 21855-025) with TPCK-trypsin (Thermo Scientific, cat 
no. 20-233) and further characterized by analyzing the viral antigenicity and sequences of HA 
genes. Sample information with clinical features of A(H1N1)pdm09 infection is summarized 
in Table 1.
Total RNA extraction and cDNA synthesis 
Viral RNA was extracted from cultured viral isolates using QIAamp Viral RNA Mini 
Kits (Qiagen, cat. no. 52904). In brief, 140 µl of a clinical specimen was mixed with AVL 
buffer, followed by 560 µl of ethanol. The resultant suspensions were applied on a QIAamp 
Mini column for RNA binding. After washing with wash buffers and eluting with TE buffer, 
the eluted viral RNA was used in the reverse transcription assay. Alternatively, automated 
extraction was conducted using a MagNa Pure LC extraction system (Roche). For cDNA 
preparation, BluePrint(TM) 1st Strand cDNA Synthesis Kit (Takara BIO Inc, cat. no. 6110) 
was used. Template viral RNA and random primers were mixed in a total volume of 10 µl. 
After incubating at 65°C for 5 minutes followed by cooling on ice, reaction buffer, reverse 
transcriptase and water were added. The resultant mixture was incubated at 30°C for 10 
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minutes, then at 42°C for 30 minutes. The obtained cDNA was used in PCR assays. To 
determine the viral genotype, partial nucleotide sequences (position 393-1182) of the HA 
genes were first analyzed by RT-PCR using primers published by WHO. Genotypes of the 
isolated viruses were then determined by blasting the sequences through the NCBI database. 
All of the A(H1N1)pdm09 isolates in this study were identified as A/California/07/2009-like 
viruses.
Hemagglutinin gene fragment amplification by PCR 
The primers specific for a fragment of HA gene of both pandemic A(H1N1)v and 
seasonal A(H1N1)v strain were as follows: H1msscp1 (5'-AGTAACACACTCTGT-3') and 
H1msscp2 (5'-ACAATGTAGGACCATGA-3'). The primers were synthesized by IBB PAN 
(Warsaw, Poland). PCR was performed in a 25 µl reaction volume with standard reagents, 0.4 
µM each primer and 1 µl of cDNA solution. The assay was performed in a GeneAmp PCR 
System 2700 (Applied Biosystems Inc., USA) according to the following procedure: 7 min. at
94C for initial denaturation, then 45 cycles of denaturation at 94C for 10 s, annealing at 
46C for 30 s and extension at 68C for 35 s. After the last cycle the reaction was completed 
by a final extension at 68C for 7 min. 
MSSCP-based minor genetic variants enrichment procedure 
The PCR products were analyzed by the MSSCP method at strictly controlled (± 
0.2ºC) gel temperature in a dedicated apparatus: DNAPointer® System/BioVectis (Warsaw, 
Poland) as described by Kaczanowski et al.25 Briefly, the PCR products were heat denatured 
and ssDNA conformers were resolved on a 9% polyacrylamide gel in native conditions (TBE 
buffer), the gel temperature decreasing during the run from the initial 15°C to 10°C to 5°C. 
Electrophoretic profiles of analyzed amplicones were compared to reference samples 
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representing seasonal: A/Brisbane/59/2007 and pandemic: A/Mexico/4486/09 A(H1N1) 
strains. Subsequently, DNA bands were visualized by silver nitrate staining (SilverStain DNA 
Kit, BioVectis, cat. no. 200-101). Fragments of the MSSCP gel containing bands of interest 
(for samples with electrophoretic profile in accordance with pandemic reference sample: the 
first ssDNA band from the bottom of the gel; for samples with electrophoretic profile distinct 
from pandemic reference sample: the first ssDNA band from the top of the gel) were cut out, 
ssDNA was eluted and re-amplified using primers and PCR conditions as described above. 
For subsequent DNA Sanger sequencing (3730xl DNA Analyzer, Applied Biosystems, 
Carlsbad, CA, USA) 1/10 vol. of obtained PCR products, purified with exonuclease I (Exo) 
and shrimp alkaline phosphatase (Sap) enzymes (Fermentas, cat. no. EN0581 and EF0511) 
was used.26 
Bioinformatic analysis of HA structures
HA structures were downloaded from the RCSB website http://www.rcsb.org (PDB accession 
codes: 3ZTN and 1QFU) and subjected to a short 200 step minimization procedure with the 
backbone atoms fixed. Minimization was done with Tripos SybylX and AMBER force field to
relax crystalographic constrains imposed especially on the surface exposed amino acid side 
chains. Next, structures where superimposed using the Matchmaker software27, by first 
creating a pairwise sequence alignment with the Needleman and Wunsch algorithm and 
BLOSUM-62 matrix, and then fitting the aligned residue pairs. RMSD between 165 aligned 
atom pairs was 1.111 A, yielding a highly matched structural alignment. The aligned 
crystallographic structures were analyzed with the emphasis on the interface between HA 
protein and neutralizing antibody chains: H and L chains from 1QFU. Volume analysis was 
conducted with VolSurf as implemented in Tripos SybylX (Tripos Inc., St. Louis, MO, USA) 
packages. UCSF Chimera was used for hydrogen bond network analysis, contact/clash 
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estimation and electrostatic surface generation.
Calculation of pepitope value and vaccine effectiveness
All calculations were based on data shown in Pan et al.24 The P-value which is used to 
measure antigenic distance between circulating and vaccine strain21 was calculated for every 
epitope of H1 (A-E) using equation 8 in reference [24]:
P-value= Number of substitutions in the epitope / Number of amino acids in the epitope.
The calculation was based on the assumption that the only difference between the 
hypothetical strain and vaccine strain are the five amino acid substitutions present in epitope 
E of H1. The Pepitope value is the highest of all P-values24. The P-value for epitope E was taken 
as the pepitope value for further calculations. As shown in chart on Figure 2 in reference [24] 
based on epidemiological data for various circulating and vaccine strains from 1982 to 2008 
taken from Table II in reference [24], vaccine effectiveness is a decreasing linear function 
(R2=0.68) of pepitope described as:
vaccine effectiveness = -1.19pepitope + 0.53.
The predicted value of vaccine effectiveness calculated by Pan et al24 was 52.7%, for pepitope = 
0.
Phylogenetic analysis of A(H1N1)pdm09 isolates
Two hundred and twenty one Taiwan origin A(H1N1) hemagglutinin nucleotide sequences 
deposited from 2009 through 2011 were downloaded from EpiFlu database. The sequences 
were aligned in Geneious Alignment Tool and duplicated sequences were removed. The 12 
unique sequences were then aligned with the five sequences from our study. After extraction, 
merged regions comprising nucleotides 183 - 291 and 364-1189 were used to create a 
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phylogenetic tree based on Neighbor-joining method with Tamura Nei genetic distance model 
using Geneious Tree Builder.
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Figure Legends
Figure 1
New genetic variants among A(H1N1)pdm09 isolates collected at Taiwan between 2009-2011
detected by MSSCP genotyping.
RT-PCR products of hemagglutinin gene obtained from pandemic Taiwan A(H1N1)pdm09 
virus isolates, as well as reference seasonal (s) and pandemic (p) strains of influenza virus 
A(H1N1)pdm09 were denatured and ssDNA’s were separated on a 9 % polyacrylamide gel 
using MSSCP method under optimum electrophoretic conditions. DNA bands were visualized
with silver stain. Strains are indicated as follows: s – reference seasonal strain, p – reference 
pandemic strains. Taiwan isolates are described with symbols listed in Table 1. Note the 
presence of five distinct MSSCP electrophoretic profiles (arrows at the bottom of the figure) 
(samples number: 2010-03994, 2011-01219, 2010-01164, 2010-05270, 2010-05347) among 
samples, which based on RT-PCR assay, were classified as A(H1N1)pdm09 strain. Dividing 
lines indicate grouping of images from different parts of the same gel.
Figure 2
Schematic representation of genetic diversity of hemagglutinin (HA) sequence in five Taiwan 
isolates of A(H1N1)v pan09 strain. 
Black arrows above and below A(H1N1)v pdm09 reference sequence indicate modified DNA 
codons. Red letters show nucleotide changes. Altered amino acids in HA protein sequence are 
also shown. Blue star over the description indicates amino acids localized in the epitope E of 
HA. Additionally, red arrows underline three point mutations, which are translated to amino 
acids in the epitope E of HA.
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Figure 3
Structure of HA-Ab complex. 
Hemagglutinin protein monomer (blue color) interacting which neutralizing antibody (red 
color). Amino acid 66, localized on the HA-Ab interface is marked in green. 
Figure 4
Phylogenetic tree of nucleotide sequences of hemagglutinin gene of Taiwan isolates of 
influenza A(H1N1)pdm09 virus. 
All sequences included in phylogenetic analysis were 935 nucleotides long. All Taiwan 
isolates deposited from 2009 through 2011 were retrieved from the EpiFlu Database. Each 
isolate (EPI210250 HA, EPI382332 HA, EPI382342 HA, EPI382415 HA, EPI190807 HA, 
EPI382397 HA, EPI382345 HA, EPI382352 HA, EPI382407 HA, EPI382412 HA, 
EPI382365 HA, EPI382375 HA) represents a number of identical sequences used in 
alignment. Isolates studied in this paper are described in Table 2. Numbers on branches 
indicate number of nucleotide substitutions per site.
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Table 1
Sample information and clinical symptoms of flu infection among A(H1N1)pdm09 Taiwan 
patients. 
Sample
number Age Sex
Date of
isolation
Geographical location of
isolation Clinical symptoms
2009-
02826 5 Male 2009-07-27 Central Taiwan
cough, fever (>38°C),
pneumonia
2009-
00940 70 Male 2009-09-10 Northern Taiwan cough, fever (>38°C)
2009-
08542 45 Male 2009-09-28 Eastern Taiwan
cough, sore throat, dyspnea,
pneumonia
2010-
03994 4 Male 2010-08-11 Southern Taiwan
cough, fever (>38°C), dyspnea,
pneumonia, respiratory failure
2010-
00842 63 Male 2010-12-20 Northern Taiwna
dyspnea, sore throat, fever,
pneumonia
2010-
06031 42 Female 2010-08-18 Northern Taiwan unavailable
2011-
02054 60 Male 2011-01-20 Central Taiwan
myalgia, cough, dyspnea,
pneumonia, sore throat, fever
(>38°C)
2011-
00623 56 Female 2011-02-09 Northern Taiwan cough, fever (>38°C), dyspnea
2011-
01219 53 Male 2011-02-10 Northern Taiwan
cough, fever (>38°C),
pneumonia
2009-
06078 10 Male 2009-08-27 Central Taiwan
cough, fever (>38°C),
pneumonia
2009-
04909 58 Female 2009-09-28 Eastern Taiwan
myalgia, dyspnea, cough, sore
throat
2009-
00937 83 Male 2009-09-09 Northern Taiwan
dyspnea, cough, fever (>38°C),
pneumonia
2009-
08575 22 Female 2009-09-20 Eastern Taiwan
myalgia, dyspnea, cough, sore
throat, pneumonia
2010-
01164 15 Female 2010-05-05 Northern Taiwan unavailable
2010-
05270 37 Male 2010-09-06 Northern Taiwan
cough, sore throat, fever
(>38°C), dyspnea, pneumonia
2010-
05347 56 Male 2010-08-12 Northern Taiwan
cough, fever (>38°C),
pneumonia
2011-
04512 38 Female 2011-01-17 Eastern Taiwan
myalgia, dyspnea, cough, sore
throat, fever (>38°C)
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2011-
02068 4 Male 2011-01-24 Central Taiwan cough, fever (>38°C), vomiting
2011-
04611 55 Male 2011-02-08 Northern Taiwan dyspnea, cough
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Table 2
Genetic diversity of HA gene fragment in Taiwan A(H1N1)pdm09 isolates. Red indicates 
mutations localized in epitope E of HA protein. Blue indicates amino acids substitutions 
preserving physico-chemical properties. Bold black font indicates synonymous amino acid 
substitutions.
Sample
number
Mutations in
nucleotide
sequence
(ref›mut)
Changes in amino
acid sequence
(ref›mut) with their
position number
Amino acid physico-
chemical properties Comments
2009-02826
2009-00940
2009-08542
2010-00842
2010-06031
2011-02054
2011-00623
2009-06078
2009-04909
2009-00937
2009-08575
2011-04512
2011-02068
2011-04611
- - - Identical to
A(H1N1)pdm09
reference sequence
2010-03994 TAC›AAC
GTA›ATA
Y›N (78)
V›I (80)
hydrophobic›
polar uncharged
hydrophobic›
hydrophobic
-
-
2011-01219 GCT›GCA
GGC›GAC
TGG›TGT
ATC›ATA
CTG›ATG
CTC›ATC
AGC›AAC
TAC›AAC
A›A (58)
G›D (59)
C›W (60)
I›I (61)
L›M (62)
L›I (70)
S›N (74)
Y›N (78)
-
aliphatic uncharged›
charged negative
sulhur-containing›
hydrophobic
-
hydrophobic›
hydrophobic
hydrophobic›
hydrophobic
polar uncharged›
polar uncharged
hydrophobic›
polar uncharged
Localized in epitope
E of HA
-
-
-
-
Localized in epitope
E and HA-Ab
interface
Localized in epitope
E of HA
-
2010-01164 AGA›AGG
GTA›GGA
R›R (45)
V›G (47)
-
hydrophobic›
aliphatic uncharged
-
Localized in epitope
E of HA
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TAC›AAC Y›N (78) hydrophobic› polar
uncharged
-
2010-05270 GCC›GAC
GCT›GCA
GGC›GAC
GAG›AAG
AGC›AAC
TAC›AAC
GTA›ATA
A›D (48)
A›A (58)
G›D (59)
E›K (66)
S›N (74)
Y›N (78)
V›I (80)
hydrophobic›
charged negative
-
aliphatic uncharged›
charged negative
charged negative›
charged positive
polar uncharged›
polar uncharged
hydrophobic›
polar uncharged
hydrophobic›
hydrophobic
Localized in epitope
E of HA
Localized in epitope
E of HA
-
Localized in epitope
E and HA-Ab
interface
Localized in epitope
E of HA
-
-
2010-05347 ATT›ATC
CCA›CCT
GAG›AAG
TAC›AAC
GTA›ATA
I›I (57)
P›P (65)
E›K (66)
Y›N (78)
V›I (80)
-
-
charged negative›
charged positive
hydrophobic›
polar uncharged
hydrophobic›
hydrophobic
Localized in epitope
E of HA
Localized in HA-Ab
interface
Localized in epitope
E and HA-Ab
interface
-
-
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We acknowledge the authors, originating and submitting laboratories of the sequences from GISAID’s EpiFlu™ Database on which this research is based. The list is detailed below.
All submitters of data may be contacted directly via the GISAID website www.gisaid.org
Segment ID             Segment Country Collection date Isolate name      Originating Lab Submitting Lab Authors
EPI382375  HA Taiwan 2010-Dec-01 A/Taiwan/66259/2010 Other Database Import "Tsao,K.-C.; Shih,S.-R.; Chen,G.-W.; Huang,C.-G.; 
Chang,S.-C.; Lin,T.-Y."
EPI382365 HA Taiwan 2010-Nov-01 A/Taiwan/3276/2010                     Other Database Import                 "Tsao,K.-C.; Shih,S.-R.; Chen,G.-W.; Huang,C.-G.; 
Chang,S.-C.; Lin,T.-Y."
EPI382412 HA Taiwan 2011-Feb-01 A/Taiwan/90284/2011 Other Database Import "Tsao,K.-C.; Shih,S.-R.; Chen,G.-W.; Huang,C.-G.; 
Chang,S.-C.; Lin,T.-Y."
EPI382407 HA Taiwan 2011-Feb-01 A/Taiwan/90252/2011 Other Database Import "Tsao,K.-C.; Shih,S.-R.; Chen,G.-W.; Huang,C.-G.; 
Chang,S.-C.; Lin,T.-Y."
EPI382352 HA Taiwan 2010-Sep-01 A/Taiwan/90149/2010 Other Database Import "Tsao,K.-C.; Shih,S.-R.; Chen,G.-W.; Huang,C.-G.; 
Chang,S.-C.; Lin,T.-Y."
EPI382345 HA Taiwan 2010-Aug-01 A/Taiwan/90112/2010 Other Database Import "Tsao,K.-C.; Shih,S.-R.; Chen,G.-W.; Huang,C.-G.; 
Chang,S.-C.; Lin,T.-Y."
EPI382397 HA Taiwan 2011-Feb-01 A/Taiwan/90187/2011 Other Database Import "Tsao,K.-C.; Shih,S.-R.; Chen,G.-W.; Huang,C.-G.; 
Chang,S.-C.; Lin,T.-Y."
EPI190807 HA Taiwan 2009-May-19 A/Taiwan/T0724/2009 Other Database Import
EPI38241 5 HA Taiwan 2011-Feb-01 A/Taiwan/65330/2011 Other Database Import "Tsao,K.-C.; Shih,S.-R.; Chen,G.-W.; Huang,C.-G.; 
Chang,S.-C.; Lin,T.-Y."
EPI382342 HA Taiwan 2010-May-01 A/Taiwan/90060/2010 Other Database Import "Tsao,K.-C.; Shih,S.-R.; Chen,G.-W.; Huang,C.-G.; 
Chang,S.-C.; Lin,T.-Y."
EPI382332 HA Taiwan 2010-Jan-01 A/Taiwan/90001/2010 Other Database Import "Tsao,K.-C.; Shih,S.-R.; Chen,G.-W.; Huang,C.-G.; 
Chang,S.-C.; Lin,T.-Y."
EPI210250 HA Taiwan 2009-Apr-08 A/Taiwan/693/2009          CDC                    WHO CCRRI
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